A Phase 2a/b Randomized Double-blind Placebo-controlled Parallel Group

Recruiting

99 years and younger

All

1 Location

Brief description of study

A study to investigate efficacy and safety of OG-6219 BID in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

Updated on 12 Apr 2023. Study ID: 853419

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2a/b Randomized Double-blind Placebo-controlled Parallel Group Multicenter Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study